P633 Choice of first biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costs

Dhar, A.(1)*;Wilson, A.(2);Reid, V.(3);Clark, T.(4);Tibbatts, C.(5);Dallongeville, A.(6);Robertson, J.(7);Eaton, J.(8);Cranmer, H.(9);Owen, G.(8);

(1)County Durham and Darlington NHS Foundation Trust, Gastroenterology Department, Darlington, United Kingdom;(2)Belfast Health & Social Care Trust, Pharmacy Department, Belfast, United Kingdom;(3)Manchester University NHS Foundation Trust, Pharmacy Department, Manchester, United Kingdom;(4)Leeds Teaching Hospital NHS Trust, Gastroenterology Department, Leeds, United Kingdom;(5)Cardiff & Vale University Health Board, Gastroenterology Department, Cardiff, United Kingdom;(6)Takeda Pharmaceuticals International AG, Portfolio & Pipeline, Zurich, United Kingdom;(7)Takeda UK Ltd, Medical, London, United Kingdom;(8)Takeda UK Ltd, Market Access, London, United Kingdom;(9)Cranmer Consultancy, Health Economics, Sheffield, United Kingdom;